Editor, Ophthalmology Times
Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470
July 20th 2025Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.
Read More
4DMT accelerating 4D-150 4FRONT phase 3 program, laying off 25% of staff
July 7th 2025The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.
Read More